Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Subscribe To Our Newsletter & Stay Updated
